Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Cash resources plus anticipated $440.0 million Ziihera GEA regulatory milestones projected to fund operations beyond 2028.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Cash resources plus anticipated $440.0 million Ziihera GEA regulatory milestones projected to fund operations beyond 2028
- Funding outlook assumes potential full execution of the 2026 Share Repurchase Program
- Milestone payments contingent on potential Ziihera approvals in the U.S., Europe, Japan, and China
- Forward-looking liquidity projection carries regulatory approval and execution risk
Item 8.01 · Other Events
- New $125.0 million share repurchase authorization, signaling capital return and potential reduction in shares outstanding
- Prior $125.0 million authorization terminated and replaced
- 2025 program repurchased 4,197,553 shares at $24.36 average, totaling $102.3 million
- Future repurchases may support per-share metrics but reduce cash available for operations or acquisitions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.